Please assess the completion status of the following clinical trial:

Trial Title: Study Effect of VIA-2291 on Vascular Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients are to be of non-childbearing potential~* Patient has suffered an ST elevation myocardial infarction (MI), non-ST elevation MI, or unstable angina 21 days (±3 days) prior to study randomization~* Patient has documented coronary artery disease~Exclusion Criteria:~* Renal insufficiency defined as creatinine \>1.5 x upper limit of normal (ULN)~* Cirrhosis, recent hepatitis, ALT \>1.5 x ULN or ALT \> 1 x ULN and at least one other liver function test~* Uncontrolled diabetes mellitus within 1 month prior to study screening~* Congestive heart failure (CHF) defined by the New York Heart Association as functional Class III or IV~* Previous coronary artery bypass graft (CABG) surgery~* Planned additional cardiac intervention~* Recurrence of ST elevation MI, non-ST elevation MI, or unstable angina less than 18 days prior to randomization~* Current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions~* Acetaminophen use in any form in the 7 days before enrollment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- VIA-2291 25 mg (Type: EXPERIMENTAL): VIA-2291 25 mg
- VIA-2291 50 mg (Type: EXPERIMENTAL): VIA-2291 50 mg
- VIA-2291 100 mg (Type: EXPERIMENTAL): VIA-2291 100 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).